World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
145
Citations
95772
World Ranking
1367
National Ranking
795

Ross L. Levine publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ross L. Levine sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 710 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ross L. Levine D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ross L. Levine sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 145 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ross L. Levine is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine, with significant contributions in biochemistry, genetics, and molecular biology. The main subfields of study include hematology, molecular biology, genetics, cancer research, and oncology.

Their work extensively addresses topics related to acute myeloid leukemia research, myeloproliferative neoplasms diagnosis and treatment, cancer genomics and diagnostics, chronic myeloid leukemia treatments, protein degradation and inhibitors, epigenetics and DNA methylation, as well as single-cell and spatial transcriptomics.

Among recent publications are the following papers:

  • Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN, 2022, Blood
  • Cancer therapy shapes the fitness landscape of clonal hematopoiesis, 2020, Nature Genetics
  • Single-cell mutation analysis of clonal evolution in myeloid malignancies, 2020, Nature
  • The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis, 2021, Nature
  • Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer, 2023, Cancer Discovery

Frequent co-authors have included:

  • Eytan M. Stein (51 publications)
  • Martin S. Tallman (41 publications)
  • Robert L. Bowman (38 publications)
  • Wenbin Xiao (38 publications)
  • Michael F. Berger (37 publications)

Ross L. Levine's publications appear most often in the following venues:

  • Blood (83 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (26 publications)
  • Blood Advances (16 publications)
  • Cancer Research (16 publications)
  • Journal of Clinical Oncology (11 publications)

Best Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori

  • The landscape of somatic copy-number alteration across human cancers

    Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei

  • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

    Ross L. Levine;Ross L. Levine;Martha Wadleigh;Jan Cools;Benjamin L. Ebert;Benjamin L. Ebert

  • Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

    Maria E. Figueroa;Omar Abdel-Wahab;Chao Lu;Patrick S. Ward

  • Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

    Jay P. Patel;Mithat Gönen;Maria E. Figueroa;Hugo Fernandez

  • The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

    Patrick S. Ward;Jay Patel;David R. Wise;Omar Abdel-Wahab

  • IDH mutation impairs histone demethylation and results in a block to cell differentiation

    Chao Lu;Patrick S. Ward;Patrick S. Ward;Gurpreet S. Kapoor;Dan Rohle;Dan Rohle

  • IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

    Sevin Turcan;Daniel Rohle;Daniel Rohle;Anuj Goenka;Logan A. Walsh

  • Clinical effect of point mutations in myelodysplastic syndromes.

    Rafael Bejar;Kristen Stevenson;Omar Abdel-Wahab;Naomi Galili

  • MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

    Yana Pikman;Benjamin H Lee;Thomas Mercher;Elizabeth McDowell

  • JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

    Linda M. Scott;Wei Tong;Ross L. Levine;Mike A. Scott

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi

  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

    Kelly Moran-Crusio;Linsey Reavie;Alan Shih;Omar Abdel-Wahab

  • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman

  • EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

    Wendy Béguelin;Relja Popovic;Matt Teater;Yanwen Jiang

  • Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

    Lambert Busque;Jay P Patel;Maria E Figueroa;Aparna Vasanthakumar

  • Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

    Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst

  • Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.

    Qian Zhang;Kai Zhao;Qicong Shen;Yanmei Han

  • Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

    Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero

  • The role of mutations in epigenetic regulators in myeloid malignancies

    Alan H. Shih;Omar Abdel-Wahab;Jay P. Patel;Ross L. Levine

Frequent Co-Authors

Omar Abdel-Wahab
Omar Abdel-Wahab Memorial Sloan Kettering Cancer Center
Martin S. Tallman
Martin S. Tallman Northwestern University
Ari Melnick
Ari Melnick Cornell University
Benjamin L. Ebert
Benjamin L. Ebert Harvard University
D. Gary Gilliland
D. Gary Gilliland Fred Hutchinson Cancer Research Center
Maria E. Arcila
Maria E. Arcila Memorial Sloan Kettering Cancer Center
Ahmet Zehir
Ahmet Zehir Natera (United States)
Scott A. Armstrong
Scott A. Armstrong Harvard University
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Richard Koche
Richard Koche Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medical careers offer diverse pathways beyond becoming a physician. Many students pursuing Medicine in the USA later seek specialized roles in healthcare administration, advanced clinical practice, or the pharmaceutical sector. Fortunately, there are flexible online degree options that can support your ambitions while managing costs and schedules.

If you are interested in healthcare management, a health care administration degree online is an accessible route. These programs focus on leadership skills, policy, and health systems, and can be completed while you work or study.

For those looking to take on upper-level roles, pursuing a master’s such as an MHA can provide a competitive advantage. Investigating mha degree cost is important, as affordability varies across institutions and scholarships.

Advanced clinical degrees like the DNP (Doctor of Nursing Practice) are also available online. Many choose cheapest dnp programs online to gain leadership, research, and practice skills without accumulating excessive debt.

Aspiring pharmacists can benefit from online pharmd programs that blend coursework with hands-on training. These options make healthcare careers more accessible for diverse learners.

Best Scientists Citing Ross L. Levine

Trending Scientists

Recently Published Articles